Programmable G‐Quadruplex@DNA Nano‐Highway Network Platform Enables One‐Pot Electrochemical Detection of Exosomes for Breast Cancer Lymph Node Metastasis Evaluation

Why It Matters

This platform offers a low‑complexity, highly sensitive method for exosome‑based cancer staging, potentially enabling routine point‑of‑care monitoring of breast‑cancer metastasis. Its speed and accuracy could accelerate personalized treatment decisions.

Key Takeaways

• One-pot sensor detects breast cancer exosomes electrochemically
• Uses aptamer-triggered hybridization chain reaction
• Sensitivity reaches 30 particles per milliliter
• Completes assay within one hour at room temperature
• Clinical validation shows >90% diagnostic concordance

Pulse Analysis

Exosomes have emerged as a rich source of tumor‑derived information, carrying proteins, nucleic acids, and lipids that reflect the state of the originating cancer cells. In breast cancer, the presence and composition of circulating exosomes correlate with lymph‑node metastasis, making them attractive targets for early diagnosis and treatment monitoring. Conventional isolation techniques such as ultracentrifugation or immuno‑affinity capture are labor‑intensive, require specialized equipment, and often suffer from low reproducibility, limiting their adoption in clinical laboratories. A rapid, label‑free detection method that maintains high specificity is therefore a critical unmet need.

The newly reported G‑quadruplex@DNA nano‑highway network (G4@DNA‑NHWN) addresses this gap by integrating an aptamer‑triggered hybridization chain reaction (HCR) with a streptavidin‑biotin scaffold to generate a protein‑decorated DNA nanostructure in a single, room‑temperature step. The network embeds split G‑quadruplex motifs that, in the absence of target vimentin, assemble into a G4‑Pb²⁺ complex producing a stable electrochemical baseline. When vimentin‑bearing exosomes bind the aptamer, the nanostructure disassembles, releasing free Pb²⁺ and altering the voltammetric signal. This mechanism yields a detection limit of 30 particles · mL⁻¹ within 60 minutes, rivaling laboratory‑grade assays while eliminating multiple washing and amplification stages.

Clinically, the platform demonstrated >90 % agreement with standard pathology across 42 patient samples, suggesting it could serve as a point‑of‑care tool for assessing breast‑cancer lymph‑node involvement. Beyond diagnostics, the DNA‑functionalized scaffold offers a modular backbone for targeted drug delivery, biosensing of other extracellular vesicle markers, or integration into wearable electrochemical devices. By reducing assay complexity and turnaround time, the technology aligns with the growing demand for decentralized testing and personalized oncology workflows, positioning it for rapid translation into hospital labs and potentially attracting investment from biotech firms focused on liquid‑biopsy solutions.